First-ever psoriasis legislation introduced in US Congress; calls for more research

26 February 2007

The first ever comprehensive psoriasis legislation has been introduced in the US House of Representatives - just as the National Psoriasis Foundation was preparing to head to Washington DC, for its fourth-annual Capitol Hill Day, scheduled for February 25-26, by Representatives David Wu (Democrat, Oregon) and Jim Gerlach (Republican, Pennsylvania).

The legislation was spearheaded by the National Psoriasis Foundation, which has been advocating for greater federal investment in psoriasis, on behalf of as many as 7.5 million Americans living with the disease, according to the National Institutes of Health's figures.

"I believe it's important to recognize the pain caused by psoriasis and psoriatic arthritis, and we have put forward this legislation to make treatments more accessible and find a cure for those living with these diseases," said Rep Wu, lead author of the bill and congressman in Portland, Oregon, where the Psoriasis Foundation is headquartered. "It is my hope that this bill will serve the needs of those afflicted and the community that supports them," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight